All In MedTech

FDA Clearance Tracker · P210019

ADVIA Centaur Anti-HBc Total (HBcT2) and Atellica IM Anti-HBc Total (HBcT2)

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Jul 27, 2022 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Jul 27, 2022

Approved (reclassified)

Time to decision

442 days

Received May 11, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P210019
Device name
ADVIA Centaur Anti-HBc Total (HBcT2) and Atellica IM Anti-HBc Total (HBcT2)
Applicant location
Tarrytown, NY
Received
May 11, 2021
Decided
Jul 27, 2022
Decision
Approved (reclassified)
Supplements
4 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3173

Every decision under product code SEI

FDA's approval statement

As written in FDA's record.

Approval for the ADVIA Centaur® HBc Total 2 (HBcT2) assay. The ADVIA Centaur HBc Total 2 (HBcT2) assay is an in vitro diagnostic immunoassay for use in the qualitative determination of total antibodies to the core antigen of the hepatitis B virus (HBV) in human adult serum and plasma (EDTA, lithium heparin, and sodium heparin) using the Approval for the ADVIA Centaur XP and ADVIA Centaur XPT systems.This assay can be used as an aid in the diagnosis of adults with acute or chronic hepatitis B virus (HBV) infection, and in the determination of the clinical status of HBV-infected individuals in conjunction with other HBV serological markers, for the laboratory diagnosis of HBV disease associated with HBV infection. This assay can also be used as an aid in the differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown.This assay is not intended for screening donors of blood or blood products or human cells, tissues, and cellular and tissue-based products (HCT/Ps).Approval for the ADVIA Centaur® HBc Total 2 Quality Control (HBcT2 QC).The ADVIA Centaur® HBc Total 2 (HBcT2) Quality Control material is for in vitro diagnostic use for monitoring the performance of the ADVIA Centaur HBc Total 2 (HBcT2) assay using the ADVIA Centaur systems.The performance of the ADVIA Centaur HBcT2 Quality Control material has not been with any other anti-HBc Total assay.Approval for the Atellica IM® HBc Total 2 (HBcT2) assay.The Atellica IM HBc Total 2 (HBcT2) assay is an in vitro diagnostic immunoassay for use in the qualitative determination of total antibodies to the core antigen of the hepatitis B virus (HBV) in human adult serum and plasma (EDTA, lithium heparin, and sodium heparin) using the Atellica IM Analyzer.This assay can be used as an aid in the diagnosis of adults with acute or chronic hepatitis B virus (HBV) infection and in the determination of the clinical status of HBV-infected individuals in conjunction with other HBV serological markers, for the laboratory diagnosis of HBV disease associated with HBV infection. This assay can also be used as an aid in the differential diagnosis in individuals displaying signs and symptoms of hepatitis in whom etiology is unknown.This assay is not intended for screening donors of blood or blood products or human cells, tissues, and cellular and tissue-based products (HCT/Ps).Approval for the Atellica IM® HBc Total 2 Quality Control (HBcT2 QC).The Atellica IM HBc Total 2 (HBcT2) Quality Control material is for in vitro diagnostic use for monitoring the performance of the Atellica IM HBc Total 2 (HBcT2) assay using the Atellica IM systems.The performance of the Atellica IM HBcT2 Quality Control material has not been with any other anti-HBc Total assay.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code SEI. The earliest in FDA's data is P000014, decided Sep 29, 2000.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Siemens Healthcare Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.